| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 1.07M | — |
| Operating expense | — | — |
| Net income | 1.48M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, LCTX returned -8.8% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -34.4% |
| 1 year | -8.8% |
| 5 years | -56.5% |
| 10 years | -57.4% |
| All-time high | $19.87 (Oct 1997) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in LCTX would be worth today ›No. Lineage Cell Therapeutics, Inc. has not paid a dividend in the past 12 months.
Lineage Cell Therapeutics, Inc. stock trades on NYSEAMERICAN under the ticker symbol LCTX.
Lineage Cell Therapeutics, Inc. is part of the Healthcare sector.
Lineage Cell Therapeutics, Inc. has a market cap of 276.93M USD, based on the latest quote.
Lineage Cell Therapeutics, Inc. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
